A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Y.J. | - |
dc.contributor.author | Chung, S.Y. | - |
dc.contributor.author | Gu, D.H. | - |
dc.contributor.author | Ko, G.J. | - |
dc.contributor.author | Pyo, H.J. | - |
dc.contributor.author | Kwon, Y.J. | - |
dc.contributor.author | Bak, Y.T. | - |
dc.contributor.author | Won, N.H. | - |
dc.date.accessioned | 2021-09-05T16:05:50Z | - |
dc.date.available | 2021-09-05T16:05:50Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/100783 | - |
dc.description.abstract | Infliximab is a chimeric anti-tumor necrosis factor-alpha monoclonal antibody. Infusion related reactions and infection are well known side effects of infliximab; however, renal complications have not been well recognized. We report on a patient with late onset-acute tubulointerstitial nephritis (ATIN) after treatment with infliximab and mesalazine for Crohn's disease. A 25-year-old woman was admitted with a purpuric rash on both lower extremities and arthralgia. She had been diagnosed with Crohn's disease 5.6 years previously and had been treated with mesalazine and infliximab. Serum creatinine level, last measured one year ago, was elevated from 0.6 mg/dL to 1.9 mg/dL. Results of urinalysis, ultrasound, and serologic examinations were normal. With a tentative diagnosis of Henoch-Schonlein purpura, oral prednisolone was given, and serum creatinine decreased to 1.46 mg/dL, but was elevated to 2.6 mg/dL again at two months after discontinuation of prednisolone. Renal biopsy indicated that ATIN was probably induced by drug, considering significant infiltration of eosinophils. Concomitant use of infliximab with mesalazine was supposed to trigger ATIN. Oral prednisolone was administered, and serum creatinine level showed partial recovery. Thus, ATIN should be suspected as a cause of renal impairment in Crohn's disease even after a long period of maintenance treatment with infliximab and mesalazine. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.subject | adalimumab | - |
dc.subject | antiinflammatory agent | - |
dc.subject | creatine | - |
dc.subject | infliximab | - |
dc.subject | mesalazine | - |
dc.subject | prednisolone | - |
dc.subject | blood | - |
dc.subject | case report | - |
dc.subject | combination drug therapy | - |
dc.subject | Crohn disease | - |
dc.subject | eosinophil | - |
dc.subject | female | - |
dc.subject | human | - |
dc.subject | immunology | - |
dc.subject | kidney | - |
dc.subject | Nephritis, Interstitial | - |
dc.subject | pathology | - |
dc.subject | Adalimumab | - |
dc.subject | Anti-Inflammatory Agents | - |
dc.subject | Creatine | - |
dc.subject | Crohn Disease | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Eosinophils | - |
dc.subject | Female | - |
dc.subject | Humans | - |
dc.subject | Infliximab | - |
dc.subject | Kidney | - |
dc.subject | Mesalamine | - |
dc.subject | Nephritis, Interstitial | - |
dc.subject | Prednisolone | - |
dc.title | A case of late onset-acute tubulointerstitial nephritis with infliximab and mesalazine treatment in a patient with Crohn's disease | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Pyo, H.J. | - |
dc.contributor.affiliatedAuthor | Kwon, Y.J. | - |
dc.contributor.affiliatedAuthor | Bak, Y.T. | - |
dc.identifier.doi | 10.4166/kjg.2014.63.5.308 | - |
dc.identifier.scopusid | 2-s2.0-85003904902 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.63, no.5, pp.308 - 312 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 63 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 308 | - |
dc.citation.endPage | 312 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001877196 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | adalimumab | - |
dc.subject.keywordPlus | antiinflammatory agent | - |
dc.subject.keywordPlus | creatine | - |
dc.subject.keywordPlus | infliximab | - |
dc.subject.keywordPlus | mesalazine | - |
dc.subject.keywordPlus | prednisolone | - |
dc.subject.keywordPlus | blood | - |
dc.subject.keywordPlus | case report | - |
dc.subject.keywordPlus | combination drug therapy | - |
dc.subject.keywordPlus | Crohn disease | - |
dc.subject.keywordPlus | eosinophil | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | immunology | - |
dc.subject.keywordPlus | kidney | - |
dc.subject.keywordPlus | Nephritis, Interstitial | - |
dc.subject.keywordPlus | pathology | - |
dc.subject.keywordPlus | Adalimumab | - |
dc.subject.keywordPlus | Anti-Inflammatory Agents | - |
dc.subject.keywordPlus | Creatine | - |
dc.subject.keywordPlus | Crohn Disease | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Eosinophils | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Infliximab | - |
dc.subject.keywordPlus | Kidney | - |
dc.subject.keywordPlus | Mesalamine | - |
dc.subject.keywordPlus | Nephritis, Interstitial | - |
dc.subject.keywordPlus | Prednisolone | - |
dc.subject.keywordAuthor | Acute tubulointerstitial nephritis | - |
dc.subject.keywordAuthor | Acute kidney injury | - |
dc.subject.keywordAuthor | Crohn disease | - |
dc.subject.keywordAuthor | Infliximab | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.